VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020
To listen via phone, please use the dial in information provided below.
Dial in Details:
Toll-Free: (877) 359-2916
International: (224) 357-2386
A webcast replay will be available on the VIVUS website for 30 days.
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about VIVUS, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “opportunity” and “should,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended
|| Investor Relations:
|Chief Financial Officer||Senior Partner|
Source: VIVUS, Inc.